PER percheron therapeutics limited

Ann: Topline Six-Month Results From Phase IIb Study of Avicursen, page-28

  1. 18,390 Posts.
    lightbulb Created with Sketch. 5240
    Well that’s the risk we take with these pre revenue biotech stocks, glad to have a few others in my spec biotech portfolio that have done a fair bit better to average it out. They do have cash in the bank to keep things running so all the best to the LT holders who continue holding.

    Order in the market and back to holiday mode (perhaps a few extra drinks today lol)
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.9¢
Change
-0.001(10.0%)
Mkt cap ! $9.786M
Open High Low Value Volume
1.0¢ 1.0¢ 0.9¢ $94.66K 10.09M

Buyers (Bids)

No. Vol. Price($)
4 661860 0.9¢
 

Sellers (Offers)

Price($) Vol. No.
1.0¢ 1588275 6
View Market Depth
Last trade - 15.52pm 27/06/2025 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.